renal transplantation
Conditions
Interventions
control group:Standard regimen treatment after renal transplantation
Experience group:After 4 weeks of standard treatment, renal transplant recipients were converted to low dose calcineurin inhibitor combined with sirolimus.
Sponsors
Beijing Chaoyang Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) Voluntarily signing the letter of informed consent; 2) Aged 18~70 years old; 3) prepare to accept end-stage renal disease patients after organ donation donor and living donor kidney transplantation after the death of citizen; 4) before operation, the group reactive antibody was less than 10%; 5) primary renal transplant patients; 6) Glomerular filtration rate was more than 45ml/min.
Exclusion criteria
Exclusion criteria: 1) Signs of systemic or local active infection; 2) chest X-ray examination showed signs of infiltration, cavitation or consolidation; 3) the primary disease of the recipient was diagnosed as focal segmental glomerulosclerosis (FSGS) or membranous proliferative glomerulonephritis (MPGN); 4) patients with multiple organ transplantation; 5) patients with triglycerides exceeding 400mg/dL (> 4.6mmol/L) and total cholesterol > 300mg/dL (> 7.8mmol/L); 6) the 24 hour urine protein was more than 500mg/d; 7) biopsy confirmed acute rejection occurred within the first 4 weeks of admission; 8) patients who were intolerant of 1.5g/d MMF within the first 4 weeks of admission; 9) renal function delayed recovery (DGF) and glomerular filtration rate (45ml/min) were less than 4 weeks before admission; 10) active hepatitis B or active hepatitis C (according to the diagnostic criteria of each center); 11) HIV positive; 12) other research drugs were used in the first 4 weeks of the group; 13) there was a history of cancer in the first 3 years (except for well treated basal cell skin cancer and squamous cell skin cancer); 14) the donor's kidney source was identical twins; 15) preparations for the use of substances known to have strong interactions with sirolimus, including antifungal agents (clotrimazole, fluconazole, itraconazole, ketoconazole, Fushita Yasu), antibiotics (clarithromycin, erythromycin, teliromycin, amidomycin), and gastrointestinal tract (Sisabi Leigh, methoxyclopramide) anticonvulsant Drugs (C Masi Bing, phenobarbital, phenytoin), antituberculous drugs: rifampicin, rifampicin, herbal preparations (Saint John grass (Hypericum perforatum, hypericin), and other drugs (bromocriptine, cimetidine, nalazol), HIV- protease inhibitors (such as rimonavir and ininavir); 16) women in pregnancy, preparation for pregnancy or lactation; Some researchers think that it is not suitable for the use of experimental drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| creatine; | — |
Countries
China
Contacts
Public ContactWang Wei
Beijing Chaoyang Hospital
Outcome results
None listed